Proteon logo     Print Page | Close Window

SEC Filings

8-K
PROTEON THERAPEUTICS INC filed this Form 8-K on 11/07/2017
Entire Document
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Proteon Therapeutics, Inc.
     
   
Date: November 7, 2017 By:  /s/ George A. Eldridge        
    George A. Eldridge
    Senior Vice President & Chief Financial Officer
   


EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release, dated November 7, 2017, issued by Proteon Therapeutics, Inc. announcing its Third Quarter 2017 Financial Results